Utilize este identificador para referenciar este registo: https://hdl.handle.net/1822/73402

TítuloSynthesis and bioactivity of new analogue of Bicyclic 1-Azafagomine
Autor(es)Akhundova, Fidan N.
Kurbanova, Malahat M.
Huseynzada, Alakbar E.
Alves, Maria José Chão
Sujayev, Afsun R.
Palavras-chaveAntibacterial activity
1-Azafagomine
Azasugars
Chiral inductor
LACASA-DA reaction
Data6-Dez-2019
EditoraWiley-VCH Verlag
RevistaChemistryselect
CitaçãoAkhundova, F. N., Kurbanova, M. M., Huseynzada, A. E., Alves, M. J., & Sujayev, A. R. (2019). Synthesis and Bioactivity of New Analogue of Bicyclic 1-Azafagomine. ChemistrySelect, 4(45), 13384-13387
Resumo(s)New (S)-(1,2,3,6-tetrahydropyridazin-3-yl)methanol was synthesized by Lewis acid catalyzed and self-assembled Diels-Alder (LACASA-DA) cycloaddition reaction using (S)-BINOL as a chiral inductor. The N-2 pyridazine position was protected, the hydroxyl group was carbonylated to form the new bicyclic structure. The protective group was removed and the double bond was dihydroxylated leading to the target compound. Removal of the protective group was performed using a newly found ecofriendly catalyst for N-Boc deprotection. The final iminosugar derivative 7 and all newly synthesized intermediates, were investigated against S. aureus and E. coli bacteria and were found to show promising activity against both gram-positive and gram-negative bacteria.
TipoArtigo
URIhttps://hdl.handle.net/1822/73402
DOI10.1002/slct.201903190
ISSN2365-6549
Versão da editorahttps://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/slct.201903190
Arbitragem científicayes
AcessoAcesso aberto
Aparece nas coleções:CDQuim - Artigos (Papers)

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
slct201903190-sup-0001-misc_information.pdf1,48 MBAdobe PDFVer/Abrir

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID